Subscribe Now!
Free Daily News, Jobs, Webcasts, Discussions
Display and Distribute
Your Job Openings
COVID-19 News
COVID-19 Webcasts

Featured Jobs

Qualified Plan Administrator

Clark Schaefer Hackett
(Cincinnati OH / Miamisburg OH / Columbus OH)

Clark Schaefer Hackett logo

Pension Administrator

KB Pension Services
(Telecommute / Bradenton FL)

KB Pension Services logo

Actuarial Consultant

Definiti-LLC
(Telecommute / University Place WA / The Woodlands TX / Erie PA / Dallas TX)

Definiti-LLC logo

Commissioner, Tax Exempt and Government Entities Division

Internal Revenue Service [IRS]
(Telecommute / Washington DC)

Internal Revenue Service [IRS] logo

Retirement Plan Consultant

Definiti
(Telecommute / Dallas TX / University Place WA / The Woodlands TX)

Definiti logo

Free Daily News and Jobs

“BenefitsLink continues to be the most valuable resource we have at the firm.”

-- An attorney subscriber

Mobile App image LinkedIn icon
Twitter icon
Facebook icon

<< Previous news item   |   Next news item >>



$89,000 Orphan Drug Gets a New Owner -- and Likely a New Price
Kaiser Health News Link to more items from this source
Mar. 17, 2017
"Marathon Pharmaceuticals' controversial $89,000-a-year drug ... is getting a new owner.... PTC Therapeutics announced plans ... to buy the Duchenne muscular dystrophy drug Emflaza from Marathon for $140 million in cash and stock. The drug's new price was not announced.... For years, many American patients have imported the generic version at a cost averaging from $1,000 to $1,600 annually. The cost typically was not covered by insurers."

Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the link above).
An important word about authorship: BenefitsLink® is providing a hypertext link to the item shown above, but is not the author of the item (unless otherwise specified).
© 2020 BenefitsLink.com, Inc.